Can piperacillin‑tazobactam cause ototoxicity?

Piperacillin-Tazobactam Does Not Cause Ototoxicity

Piperacillin-tazobactam is not associated with ototoxicity and does not require audiometric monitoring. The FDA-approved drug label for piperacillin-tazobactam does not list ototoxicity as a recognized adverse effect 1.

Evidence Base

The FDA labeling for piperacillin-tazobactam comprehensively outlines its adverse effect profile, including hypersensitivity reactions, severe cutaneous reactions, hemophagocytic lymphohistiocytosis, rhabdomyolysis, hematologic abnormalities, central nervous system effects (neuromuscular excitability and seizures), and nephrotoxicity—but ototoxicity is notably absent 1.

Aminoglycoside Context

The confusion likely arises from piperacillin-tazobactam's frequent co-administration with aminoglycosides (amikacin, gentamicin) for serious infections. The FDA label specifically addresses Y-site compatibility with aminoglycosides but does not suggest any additive ototoxic risk 1.

Aminoglycosides themselves are highly ototoxic:

• Amikacin causes irreversible vestibulocochlear nerve damage, with ototoxicity (primarily auditory > vestibular) occurring more frequently with prolonged use and older age 2, 3
• High-frequency hearing loss occurred in 24% of patients receiving amikacin in one report 3
• Streptomycin causes ototoxicity including vestibular and hearing disturbances, with risk increasing with age and cumulative doses above 100-120 g 4, 3
• Capreomycin causes vestibular disturbances, tinnitus, and deafness, particularly in elderly persons or those with renal impairment 3

Monitoring Requirements

For aminoglycosides (not piperacillin-tazobactam):

• Baseline audiometry before starting treatment
• Monthly audiometry during aminoglycoside therapy
• Final audiometry 2 months after the last dose
• Ototoxicity defined as 20 dB loss from baseline at any one frequency or 10 dB loss at two adjacent frequencies 2

For piperacillin-tazobactam alone:

• No audiometric monitoring required
• Monitor for nephrotoxicity, particularly in critically ill patients 1
• Monitor renal function, hematologic parameters, and neurologic status in high-risk patients

Clinical Implications

If a patient on piperacillin-tazobactam develops hearing loss or tinnitus, investigate alternative causes:

• Concomitant aminoglycoside use
• Loop diuretics (furosemide, ethacrynic acid), which increase aminoglycoside ototoxicity risk 2
• Cisplatin or other ototoxic chemotherapy agents 5, 6, 7
• Underlying conditions or other medications

The single topical study showing piperacillin-tazobactam did not cause ototoxicity in guinea pigs when applied to the middle ear further supports its lack of ototoxic potential 8.